Lyell Immunopharma (LYEL) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to -$319.6 million.
- Lyell Immunopharma's Enterprise Value rose 2744.84% to -$319.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.6 million, marking a year-over-year increase of 2744.84%. This contributed to the annual value of -$370.5 million for FY2024, which is 3216.56% up from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Enterprise Value is -$319.6 million, which was up 2744.84% from -$276.8 million recorded in Q2 2025.
- Lyell Immunopharma's 5-year Enterprise Value high stood at -$244.4 million for Q1 2021, and its period low was -$824.5 million during Q2 2021.
- Its 5-year average for Enterprise Value is -$521.9 million, with a median of -$575.4 million in 2023.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 35887.13% in 2021, then skyrocketed by 4364.1% in 2025.
- Quarter analysis of 5 years shows Lyell Immunopharma's Enterprise Value stood at -$614.8 million in 2021, then fell by 4.12% to -$640.2 million in 2022, then rose by 14.67% to -$546.2 million in 2023, then surged by 32.17% to -$370.5 million in 2024, then increased by 13.74% to -$319.6 million in 2025.
- Its Enterprise Value stands at -$319.6 million for Q3 2025, versus -$276.8 million for Q2 2025 and -$301.2 million for Q1 2025.